Related Experiment Video
Updated: Mar 6, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.8K
Neuropeptides as a Marker for Chronic Headache.
Nuria Riesco1, Eva Cernuda-Morollón1, Julio Pascual2
1Service of Neurology, University Hospital Central de Asturias, Oviedo, Spain.
Current Pain and Headache Reports
|March 11, 2017
Summary
Calcitonin gene-related peptide (CGRP) shows promise as a biomarker for chronic migraine, but its levels aren't elevated in all patients. Further research is needed to explore other trigemino-vascular system neuropeptides for headache diagnosis.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Headache Pathophysiology
Background:
- The trigemino-vascular system (TVS) plays a crucial role in primary headache disorders, particularly chronic migraine (CM).
- Neuropeptides released by the TVS are being investigated as potential biomarkers for CM.
- Understanding these neuropeptides is key to improving CM diagnosis and treatment.
Purpose of the Study:
- To review and revise current evidence on trigemino-vascular system (TVS) neuropeptides.
- To evaluate their potential as biomarkers for chronic primary headaches, focusing on chronic migraine (CM).
Main Methods:
- Systematic review of existing scientific literature.
- Analysis of studies measuring neuropeptide levels in patients with chronic primary headaches.
- Evaluation of the sensitivity and specificity of various neuropeptides as biomarkers.
Main Results:
- Calcitonin gene-related peptide (CGRP) shows potential as a biomarker for acute migraine and CM, but is not elevated in 20-30% of CM patients.
- Data for other sensory neuropeptides like neurokinin and substance P are inconsistent or lacking.
- Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) show some promise but require further investigation.
- S100B, a marker of glial activation, has yielded inconsistent results in migraine studies.
Conclusions:
- Current evidence for TVS neuropeptides as CM biomarkers, including CGRP, should be interpreted with caution.
- Uncertainties remain regarding TVS activation, laboratory test reliability, peptide half-life, and the influence of treatments.
- Further research is necessary to validate these neuropeptides and determine their specificity for migraine versus other headache types.
Related Concept Videos
01:25Analgesia and Pain Management
2.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.5K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
668
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
668